Mammary Cell News 9.22 June 8, 2017 | |
| |
TOP STORYScientists describe a PEG engager that simultaneously binds polyethylene glycol and epidermal growth factor receptor (EGFR) to deliver PEGylated nanomedicines to EGFR+ triple-negative breast cancer (TNBC). The PEG engager displayed conditional internalization by remaining on the surface of TNBC cells until contact with PEGylated nanocarriers triggered rapid engulfment of nanocargos. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHLoss of EphA2 function in both human and genetically engineered mouse models of triple-negative breast cancer reduced tumor growth in culture and in vivo. Mechanistically, targeting EphA2 impaired cell cycle progression through S-phase via downregulation of c-Myc and stabilization of the cyclin-dependent kinase inhibitor p27/KIP1. [Oncogene] Full Article Researchers showed that semaphorin 3B is a direct target of GATA3 transcriptional activity. GATA3 is a key transcription factor that regulates genes involved in mammary luminal cell differentiation and tumor suppression. [Oncogene] Abstract The effect of the altering expression of microRNA-7 (miR-7) on migration, invasion, proliferation, interaction and underlying molecular mechanism of breast cancer cells and endothelial cells was investigated after treatment with the synthesized mimic of miR-7. [Br J Cancer] Abstract MicroRNA (miRNA) array analysis was performed to search for metastasis-associated miRNAs in triple-negative breast cancer (TNBC). The miR-211-5p expression in tumor tissues, adjacent non-tumorous breast tissues of TNBC patients and cell lines were evaluated by real-time PCR. [Br J Cancer] Abstract Scientists found that combination of ω-3 free fatty acids and all-trans retinoic acid exhibited synergistic inhibition of cell growth in three subtypes of human breast cancer cell lines. [Sci Rep] Full Article Investigators found that β-lapachone exerted significant anti-proliferation and anti-metastasis effects in breast cancer cell lines due to its effects on NQO1 expression. [Sci Rep] Full Article Diallyl trisulfide dose-dependently inhibited hypoxia-inducible factor-1α (HIF-1α) transcriptional activity and hypoxia-induced hematogenous metastasis of MDA-MB-231 cells. It reduced the protein expression of HIF-1α, which did not involve inhibition of HIF-1α mRNA expression or ubiquitin proteasome degradation. [Mol Carcinog] Abstract CLINICAL RESEARCHOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation Investigators conducted a randomized, open-label, Phase III trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2–negative metastatic breast cancer who had received no more than two previous chemotherapy regimens for metastatic disease. [N Engl J Med] Full Article | Press Release Researchers analyzed the HER2 status of circulating tumor cells (CTCs) in patients with HER2-positive primary breast cancer at the time of diagnosis. They assessed potential discordance of HER2 status between primary tumor and CTCs, as this may have important implications for the use of HER2-targeted therapy. [PLoS One] Full Article | |
| |
REVIEWSInflammatory Breast Cancer: A Model for Investigating Cluster-Based Dissemination Clusters of circulating tumor cells, although many fewer in number, possess much higher metastatic potential as compared to that of individual circulating tumor cells. The authors highlight recent insights into molecular mechanisms that can enable the formation of these clusters—hybrid epithelial/mesenchymal phenotype of cells that couples their ability to migrate and adhere, and intercellular communication that can spatially coordinate the cluster formation and provide survival signals to cancer cells. [npj Breast Cancer] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSNovartis announced updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali® plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2–) advanced or metastatic breast cancer. [Press release from Novartis discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Scientists presented results of the Phase III OlympiAD trial demonstrating for the first time that olaparib is superior to chemotherapy in patients with BRCA-related advanced breast cancer. [Press release from Penn Medicine discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Merck and QuantumLeap Healthcare Collaborative announced results from the Phase II I-SPY 2 TRIAL investigating KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with standard therapy as a neoadjuvant treatment for patients with locally advanced triple-negative breast cancer or hormone receptor-positive/HER2-negative breast cancer. [Press release from Merck Sharp & Dohme Corp. discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed Daiichi Sankyo Company, Limited announced smart chemotherapy DS-8201 demonstrated a favorable safety profile and promising antitumor activity in patients with HER2-expressing tumors, including pre-treated metastatic breast and gastric cancer. [Press release from Daiichi Sankyo Company, Limited discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Eli Lilly and Company announced that results from the Phase III MONARCH 2 study showed that abemaciclib, a cyclin-dependent kinase 4 & 6 inhibitor, in combination with fulvestrant, significantly improved progression-free survival compared to treatment with fulvestrant alone in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy. [Press release from Eli Lilly and Company discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Pfizer Inc. announced Phase II data showing that its investigational, dual-mechanism poly ADP ribose polymerase (PARP) inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline BRCA1/2-positive advanced breast cancer. [Press release from Pfizer Inc. discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Puma Biotechnology, Inc. announced the presentation of positive results from an ongoing Phase II clinical trial of Puma’s investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. [Press release from Puma Biotechnology, Inc. discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release | |
| |
INDUSTRY NEWSYale School of Medicine Expands Partnership to Promote Clinical Trials and Training in Puerto Rico An expanded partnership between the Yale School of Medicine and research institutions in Puerto Rico is set to foster collaborative clinical research and training opportunities in both countries. [Yale University] Press Release The Indo-American Cancer Association (IACA) honored City of Hope’s Ravi Salgia, M.D., Ph.D., with the IACA Award for Outstanding Contributions to Oncology during its annual meeting. [The Indo-American Cancer Association (Business Wire Inc.)] Press Release | |
| |
POLICY NEWSNSF Offers Arm’s-Length Defense of Trump’s 2018 Request President Donald Trump’s proposal for an 11.3% cut in spending at the National Science Foundation (NSF) may be dead on arrival in Congress. But that doesn’t mean congressional appropriators will be able to avoid any squeeze on NSF’s budget. Representative John Culberson, who chairs the House of Representatives spending panel that oversees NSF, opened a hearing yesterday on NSF’s 2018 budget request by saying he will work “to ensure NSF is appropriately funded” in the fiscal year. But after the hearing, Culberson declined to say whether that would require preserving its 2017 budget of $7.47 billion. [ScienceInsider] Editorial Critics Challenge NIH Finding That Bigger Labs Aren’t Necessarily Better A strident debate has erupted among biomedical researchers over a proposed National Institutes of Health (NIH) policy that would shift money from richer to poorer labs. The policy—which would limit investigators to the equivalent of three NIH grants—is based largely on an agency-led analysis of lab productivity. It found that once an NIH-funded lab grows to a certain size, each additional grant produces a smaller productivity boost. But NIH’s study, and one graph in particular, has drawn widespread criticism. [ScienceInsider] Editorial Trump Retains Collins as NIH Director President Donald Trump announced that he is keeping Francis Collins as director of the National Institutes of Health (NIH). Collins, who was appointed by former President Barack Obama in 2009, was asked to stay on temporarily after the election. The decision comes despite a recent call from some conservative members of Congress to fire Collins because he supports embryonic stem cell research. Collins has said he would return to full-time research if Trump asked him to step down. [ScienceInsider] Editorial
| |
EVENTSNEW Cold Spring Harbor Stem Cell Biology Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Clinician Investigator – Breast Cancer Research (Mayo Clinic) NEW Cancer Bioinformatician – Breast Cancer (Institute of Cancer Research) Postdoctoral Training Fellow – Breast Cancer (Institute of Cancer Research) Postdoctoral Research Associate – Breast Cancer (University of Nebraska Medical Center) Research Position – Translational Breast Cancer Research (Northwestern University) Postdoctoral Training Fellow – Cancer Metabolism (The Francis Crick Institute) Postdoctoral Fellow – Metastatic Breast Cancer Stem Cells (Memorial Sloan-Kettering Cancer Center) Statistical Bioinformatician – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Positions – Cancer Research (Baylor College of Medicine) Researcher – Tumor Microenvironment and Invasion Program (SUNY Upstate Medical University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|